These innovative drugs , including Rybelsus and others in the GLP-1 class, are primarily approved to treat type 2 glucose control. However , their metabolic benefits have created significant attention https://glp1538957.mpeblog.com/77992400/semaglutide-and-glp-1-receptor-key-people-want-regarding-learn